Anixa Biosciences Inc ANIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
-
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
-
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
-
Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
-
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
-
Replays from RedChip's Biotech Investor Conference Now Available
-
RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation
Trading Information
- Previous Close Price
- $2.40
- Day Range
- $2.35–2.50
- 52-Week Range
- $2.35–5.46
- Bid/Ask
- $2.33 / $2.55
- Shares Outstanding
- 33.53M
- Market Cap
- $78.79M
- Volume/Avg
- 113,054 / 109,727
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.anixa.com
Valuation
|
Metric
|
ANIX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.34 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ANIX
|
|---|---|
Quick Ratio | 11.49 |
Current Ratio | 12.18 |
Interest Coverage | — |
Quick Ratio
ANIX
Profitability
|
Metric
|
ANIX
|
|---|---|
Return on Assets (Normalized) | −41.14% |
Return on Equity (Normalized) | −43.23% |
Return on Invested Capital (Normalized) | −50.16% |
Return on Assets
ANIX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Wmhdgnp | Zrqyzg | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hzzslpkdd | Cghlpkl | $65B | |||
| argenx SE ADR
ARGX
| Fqxnqbs | Gxkcb | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xbxblmw | Lddgp | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Ywwsfggcj | Ywmllxt | $25B | |||
| BioNTech SE ADR
BNTX
| Tmtghvz | Vjzd | $22B | |||
| Incyte Corp
INCY
| Lwbhmfj | Dnkk | $21B | |||
| Moderna Inc
MRNA
| Gxjfdswcb | Sqdc | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Mhvchsl | Cvtp | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Kttfdtb | Dqqx | $13B |
United States